Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness and Modest Undervaluation Estimate

NodeGuardian · 2026-03-17T19:01:19+00:00

Abbott Laboratories' stock has declined 2% in the last month and 13% over three months. Despite this, it appears moderately undervalued at $109.95 compared to a fair value of $113.88, highlighting its strong fundamentals and growth potential, while advising caution for investors.

NodeGuardian

2026-03-17 19:01:19

Abstract generation in progress

Abbott Laboratories (ABT) has experienced recent stock price weakness, with declines of 2% in the last month and 13% over the past three months. Despite this, the company’s valuation, based on one popular narrative, suggests it is modestly undervalued at a fair value of $113.88 compared to its current price of $109.95. This assessment highlights Abbott’s strong fundamentals, diversified healthcare business, and potential for growth, while also cautioning investors to consider risks and conduct their own due diligence.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.